California-based provider of workforce mental health solutions for health plans and employers, Lyra Health, has extended its services to support individuals struggling to overcome stimulants, nicotine, cannabis, and opioid addiction.
Building on the company’s Lyra Renew for alcohol use disorder success, the expanded program will allow all members from across the United States access to science-backed therapies for a myriad of substance use disorders (SUD). According to the 2023 National Survey on Drug Use and Health (NSDUH), substance use disorder has impacted over 23 million employees across the United States.
Affected individuals and their families face significant challenges in finding adequate treatment options critical for addressing the interconnected problems associated with SUD. As a result, individuals struggling with addiction and other challenges associated with drug use fail to recover, ending up with exacerbated symptoms and use.
For employers, prolonged absenteeism, high safety risks, high healthcare costs, and diminished productivity result in a profound impact on their Businesses.
Lyra’s Healthcare Services for Substance Use Disorder
Lyra Health addresses substance use disorder through multiple approaches. It allows the affected individuals access to full-spectrum personalized care and higher levels of care focused on improving mental health outcomes.
Full-spectrum care is delivered through the company’s Lyra Clinical Associates, which allows members to access intensive treatments by linking them to a wide range of higher care levels, including residential treatment and inpatient and outpatient care programs.
In addition to the broader SUD support programs, Lyra is working to introduce a dedicated service called “Nicotine Quitline” to replace the traditional method. This service will offer an immediate, personalized quit plan, expert-crafted resources, and coping strategies.